Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome-Reference-Cited by-同舟云学术

Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome

Published:2018-02-15 Issue:5 Volume:61 Page:1027-1036
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Habeb Abdelhadi M., ,Flanagan Sarah E.,Zulali Mohamed A.,Abdullah Mohamed A.,Pomahačová Renata,Boyadzhiev Veselin,Colindres Lesby E.,Godoy Guillermo V.,Vasanthi Thiruvengadam,Al Saif Ramlah,Setoodeh Aria,Haghighi Amirreza,Haghighi Alireza,Shaalan Yomna,Hattersley Andrew T.,Ellard Sian,De Franco Elisa

Funder

the wellcome Trust

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/article/10.1007/s00125-018-4554-x/fulltext.html

Reference27 articles.

1. Diaz GA, Banikazemi M, Oishi K, Desnick RJ, Gelb BD (1999) Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet 22:309–312

2. Fleming JC, Tartaglini E, Steinkamp MP, Schorderet DF, Cohen N, Neufeld EJ (1999) The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nat Genet 22:305–308

3. Labay V, Raz T, Baron D et al (1999) Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 22:300–304